Anavex Life Sciences Corp (AVXL)

[Gator328]

Good point. Devil’s advocate…wouldn’t it be equally or nearly as strange for the company to run another AD trial immediately after submitting an NDA for the same indication? Could it be that they are confident in the Alzheimer’s data and no longer feel the need to rush through an AD trial with A371, so now they can focus on other diseases such as schizophrenia?

I don’t think Anavex will unilaterally decide to run another trial until after the FDA requires them to do so. I think Anavex takes its shot on goal first with the NDA…unless the plan all along is to submit Rett first in which case another AD trial isn’t as big of a deal if it has approval for another disease